Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jun 1, 2011


Affymetrix announced this week that President and CEO Kevin King will step down at the end of June to "pursue other interests."

King will be replaced by Dionex President and CEO Frank Witney, who some years ago, served as Affymetrix's executive VP and COO.

BioMarker Strategies announced that Douglas Clark will become the company's chief medical officer and acting CEO starting July 1. Clark is currently a professor of pathology and oncology at The Johns Hopkins Medical Institutions, where from 2002 to 2010 he served as the director of the cytopathology division. He will be taking a leave of absence from Johns Hopkins to join BioMarker Strategies full time.

Additionally, BioMarker Strategies has appointed Glenn Miller, VP and head of strategy, portfolio, and alliances for personalized healthcare & biomarkers at AstraZeneca Pharmaceuticals, as the chairman of its board of directors. Miller previously served on BioMarker Strategies' scientific advisory board.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.